SecProbe.io

CORRESP
1
filename1.htm

Zaxis International Inc.

7 Imber Street

Petach Tivka, 4951141 Israel

October 2, 2015

United States Securities and Exchange Commission

Washington, D.C. 20549

Mail Stop 3561

Re: Zaxis International Inc.

Registration Statement on Form S-1

Filed August 5, 2015

File No. 333-206105

Ladies and Gentlemen:

We are submitting this letter in response to the staff's comment letter dated
September 4, 2015 addressed to Zaxis International Inc. (the "Registrant"). For
the convenience of the staff we have included each staff comment, numbered
sequentially, followed by our response, also numbered sequentially.

General

Comment 1. Please update your financial statements as required by Rule 8-08 of
Regulation S-X and update the related information in your filing, such as your
Management Discussion and

Analysis section, accordingly.

Response 1. We have updated the financial statements as required by Rule 8-08 of
Regulation S-X including the disclosure under MD&A, through the period ended
June 30, 2015.

Prospectus Cover Page

Comment 2. We note disclosures throughout your filing indicating that you are a
shell Registrant. Stockholders who receive shares of common stock from a shell
Registrant are considered underwriters in connection with any resale of those
shares of common stock. Please refer to SEC Release 33-8869 (2007). Accordingly,
please revise your prospectus as follows:

Please revise your disclosure to state that your selling shareholders are
underwriters, not "may be deemed" to be underwriters as disclosed on page 23.
Please identify your selling shareholders as underwriters on the prospectus
cover page, under the Selling Shareholders and Plan of Distribution sections,
and elsewhere, as appropriate.

Please revise your disclosure to state that the selling shareholders must offer
and sell their shares for a fixed price for the duration of the offering and
disclose the price at which the selling shareholders will offer their shares. In
this regard, please revise throughout the prospectus to remove any and all
indications that selling shareholders have the ability to sell their shares at
market prices. Please note that the shares must be offered at a fixed price
because the Registrant is not eligible to make an at-the-market offering under
Rule 415(a)(1)(x) of Regulation C.

Response 2. In response to staff comment 2, please note that we have updated as
well as corrected the disclosure contained in the registration statement filed
on August 5, 2015 to properly reflect that the Registrant is no longer a shell
Registrant. In connection with and following the closing on July 14, 2015, of
the Share Exchange Agreement between the Registrant and Emerald Medical
Applications Ltd. ("Emerald"), the Registrant's wholly-owned Israeli subsidiary,
and the business developments of Emerald both prior and subsequent to the
closing, as more fully discussed in response to comment 3 below and throughout
the registration statement, it is our position that the Registrant ceased to be
a shell Registrant.

In support of the Registrant's position, we address the staff's attention to the
new and revised disclosure under "Prospectus Summary"; "Description of Business" and "Management's
Discussion and Analysis" as follows:

(i) Emerald has completed development of a commercially ready model of its
DermaCompare Technology which is presently being marketed;

(ii) Emerald has entered into several distribution agreements for marketing
DermaCompare in several European countries, Australia, New Zealand and Oceania,
and is negotiating for additional distribution agreements in North America,
Latin America, Southern Africa, in other European countries and elsewhere;

(iii) Emerald in continuing to work on development of "next generation"
DermaCompare Technology, with enhanced features;

(iv) As a subsidiary of the Registrant, a reporting public Registrant, Emerald
now has access to financial resources far in excess of those available to it
while it was a private Registrant, including funding from present shareholders
of the Registrant through the exercise of warrants and/or the issuance of new
equity or debt securities and through the public market.

For the foregoing reasons, as well as our response to comment 3 below, and based
upon the revised disclosure throughout the S-1, we have deleted disclosure that
the Registrant is a shell Registrant and, therefore, have not included the
suggested disclosure in comment 2 that the "selling shareholders are
underwriters" or that "selling shareholders must offer and sell their shares for
a fixed price for the duration of the offering."

Management's Discussion and Analysis, page 79

Comment 3. Please revise your disclosure to clarify whether you have established
any formalized agreements to sell your products and services.

Response 3. We have revised and updated the disclosure under "Prospectus
Summary," "Description of Business" and "Management's Discussion and Analysis"
regarding the establishment of formalized agreements to distribute the
Registrant's DermaCompare Technology products and services.

Specifically, we have included the following disclosure:

In furtherance of our business plan, which has resulted in us becoming an
operating company, Emerald has entered into a series of agreements with
unaffiliated third parties for the distribution of its DermaCompare Technology,
as follows:

1. On August 12, 2013, Emerald entered into an exclusive distribution with Derma
Italy Sri, organized under the laws of the Italy ("Derma Italy"), pursuant to
which Derma Italy was granted exclusive distribution rights in Italy;

2. On December 1, 2013, Emerald entered into a distribution agreement with S.
Bokhorst - Creatiekracht, organized under the laws of the Netherlands, pursuant
to which S. Bokhorst was granted exclusive distribution in the Netherlands;

3. On February 6, 2014, Emerald entered into a distribution agreement with
Medical Edge Pty Ltd, organized under the laws of Australia ("Medical Edge"),
pursuant to which Medical Edge was granted exclusive distribution rights in the
markets of Australia, New Zealand and Oceania; and

4. On January 14, 2015, Emerald entered into a Project Agreement with Realize
S.A. and Ubitech, entities engaged in IT related to medical technology in
Greece, and MEDISP and MPUoP, academic and research institutes in Greece
(collectively, the "Greek Partners"). Emerald and the Greek Partners anticipate
imminent grants from the Office of Chief Scientist of the State of Israel and
the General Secretariat for Research and Technology of Greece, respectively, the
proceeds of which will be used for development of enhanced smartphone
applications for diagnosis of early stage Melanoma.

Utilizing capital raised prior to and subsequent to the closing of the Share
Exchange Agreement, Emerald completed the development of a commercial model of
its DermaCompare Product and has commenced marketing efforts. Emerald is
continuing to negotiate additional distribution agreements for territories
including North America, Latin America, Southern Africa, Israel and elsewhere in
Europe, among other countries and regions.

Emerald fully expects to significantly increase the level of its business
activities during the 4th quarter of 2015 and expects to generate significant
revenues from its DermaCompare Technology commencing in or before the first half
of fiscal 2016. Emerald is continuing to work on development of
the "next generation" DermaCompare Technology, with enhanced features.

We have also filed as exhibits 10.13 through 10.16 to the registration statement each of the
above-referenced material agreements.

The Registrant acknowledges that since the Registrant and its management are in
possession of all facts relating to a Registrant's disclosure, the Registrant
and its management are responsible for the accuracy and adequacy of the
disclosures they have made.

The Registrant acknowledges that:

should the Commission or the staff, acting pursuant to delegated authority,
declare the filing effective, it does not foreclose the Commission from taking
any action with respect to the filing;

the action of the Commission or the staff, acting pursuant to delegated
authority, in declaring the filing effective, does not relieve the Registrant
from its full responsibility for the adequacy and accuracy of the disclosure in
the filing; and

the Registrant may not assert staff comments and the declaration of
effectiveness as a defense in any proceeding initiated by the Commission or any
person under the federal securities laws of the United States.

Respectfully submitted,

/s/: Lior Wayn

Lior Wayn, CEO